2076975 2077203
최종편집 2024-03-29 13:17 (금)
Chronic Hepatitis B treatmentㆍSkyrizi get expanded insurance benefits, Reva-K receives new benefit
상태바
Chronic Hepatitis B treatmentㆍSkyrizi get expanded insurance benefits, Reva-K receives new benefit
  • Jaehoon SongㆍHyeokgi Lee, Newsmp
  • 승인 2023.02.23 01:00
  • 댓글 0
이 기사를 공유합니다

Skyrizi, approved for active and progressive psoriatic arthritis… Liver biopsy for hepatitis B treatment

[NEWSMP] Benefit standards for Rebamipide 0.1g/5ml, Samil Pharmaceutical’s Reva-K Eye Drops and Kukjepharm's Reba-eye Eye Drops 2%, will be newly established.

AbbVie’s interleukin-23 inhibitor Skyrizi (ingredient: risankizumab) is expected to expand its insurance benefits to psoriatic arthritis.

Oral hepatitis B treatments alleviate liver function (AST, ALT) and hepatitis B virus levels.

On the 15th, the Ministry of Health and Welfare revised and issued a revision of the ‘Pharmaceutical benefit list and the table of the upper limit of benefits.’

According to the announcement, benefits for rebamipide 0.1g/5ml are recognized when administered to improve corneal epithelial disorders in adult ocular anterior patients. However, combined therapy of mucin secretion enhancers is not recognized.

Skyrizi’s benefit expands from psoriasis to psoriatic arthritis.

Subjects are active and progressive psoriatic arthritis patients who have an insufficient response to one or more tumor necrosis factor-alpha inhibitors (TNF-α inhibitors) or IL-17 was insufficient or in cases where patients had to stop treatment due to side effects, and this is set in the same way as Tremfya (ingredient: guselkumab).

If the active joint count is reduced by more than 30% six months after administrating Skyrizi, additional six months of administration are recognized, and then continuous administration is recognized if the first six months of evaluation results are maintained.

Oral hepatitis B treatments get expanded standards for liver and HBV-DNA levels.

Previously, in patients with chronic active hepatitis B with HBV-DNA of 20,000 IU/mL or more as e antigen-negative, benefits were recognized only when AST (Aspartate Transaminase) or ALT (Alanine Transaminase) was 80 or more.

In the revised notice, insurance benefits were recognized for patients with an AST or ALT level of 40-80 and a liver biopsy showing moderate or higher inflammatory necrosis (A2 or higher) or periportal fibrosis (F2 or higher).

If liver biopsy is unsuitable, Liver Fibroscan or Magnetic Resonance Elastography are acceptable.

In addition, in the past, in the case of chronic active hepatitis B patients with compensated liver cirrhosis, benefits were recognized only when HBV-DNA was 20,000 IU/mL, but in the revised notice, it was expanded to HBA-DNA-positive cases, which were considered the same as patients with decompensated cirrhosis.

 

 

 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.